PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction by Simon Rauterberg, Simon Rauterberg, Carmen Härdtner, Jennifer Hein, Paola Schrepf, Remi Peyronnet, Christoph Koentges, Tamara A. Vico, Carolin Ehlert, Bianca Dufner, Diana Lindner, Constantin von zur Mühlen, Dennis Wolf, Dirk Westermann, Ingo Hilgendorf, Alexander von Ehr

Subjects: “…PCSK9…”
Get full text

PCSK9: A Potential Therapeutic Target for Sepsis by Yuan Yuan, Wei Wu, Shanshan Sun, Yi Zhang, Zhi Chen

“…Proprotein convertase subtilisin/kexin type 9 (PCSK9) is often upregulated in the presence of sepsis and infectious diseases. …”
Get full text

Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats by Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Elham Abdollahi, Maciej Banach, Amirhossein Sahebkar

“…Two weeks after the last vaccination, anti-PCSK9 antibody titers, PCSK9 targeting, and inhibition of PCSK9–low-density lipoprotein receptor (LDLR) interaction were evaluated. …”
Get full text

PCSK9 affects vascular senescence through the SIRT1 pathway by Yuqin Wang, Shaoqing Cao, Zhangyu Wang, Chengsi Li, Jiangping Ye, Yehong Liu, Tianhui Jin, Yuting Zhou, Wentao Su, Gangjun Zong

“…The senescent state of mice was delayed under PCSK9 inhibitor treatment, and the expression of P16, P21, and P53 proteins in senescent cells was increased because LPS induction stimulated PCSK9 activation. …”
Get full text

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation by Elena Dozio, Massimiliano Ruscica, Elena Vianello, Chiara Macchi, Clementina Sitzia, Gerd Schmitz, Lorenza Tacchini, Massimiliano M. Corsi Romanelli

“…No association was found with the circulating PCSK9 level. The expression of PCSK9 in EAT argues that PCSK9 is part of the EAT secretome and EAT inflammation is associated with local PCSK9 expression, regardless of circulating PCSK9 levels. …”
Get full text

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice by Xue-Ying Zhang, Qing-Qing Lu, Yan-Jie Li, Shan-Rui Shi, Chao-Nan Ma, Miao Miao, Shou-Dong Guo

Subjects: Get full text

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy by Na Cui, Yonghao Feng, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen, Xiaohong Shi

“…The role of PCSK9 in diabetic peripheral neuropathy is still unclear. …”
Get full text

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection by B.-O. Stüben, D. P. Hoyer, S. Radunz, F. Saner, H. Schmidt, H. A. Baba, J. W. Treckmann, L. I. Mazilescu

Get full text

Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children by Olesya Fedoryak, Charles Arama, Issa Diarra, Bouréma Kouriba, Michel Chrétien, Majambu Mbikay

“…Recent evidence suggests that proprotein convertase subtilisin/kexin type 9 (PCSK9), a downmodulator of cellular uptake of blood cholesterol, also negatively impacts host immune response to microbial infection. …”
Get full text

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy by Apisitt Thaiprayoon, Yodpong Chantarasorn, Worrapoj Oonanant, Anongnard Kasorn, Phoomintara Longsompurana, Satita Tapaneeyakorn, Pinpunya Riangrungroj, Fabien Loison, Andrew C. Kruse, Matthew P. DeLisa, Dujduan Waraho-Zhmayev

“…All three clones bound to PCSK9 and blocked the interaction between the low-density lipoprotein receptor (LDLR) and either wild-type PCSK9 or the D374Y mutant. …”
Get full text

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System by Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu

“…Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). …”
Get full text

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease by Cristiana-Elena Vlad, Liliana Foia, Roxana Popescu, Iuliu Ivanov, Mihaela Catalina Luca, Carmen Delianu, Vasilica Toma, Cristian Statescu, Ciprian Rezus, Laura Florea

“…Nontraditional cardiovascular risk factors as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and the proprotein convertase subtilisin/kexin type 9 (PCSK9) increase the prevalence of cardiovascular mortality in chronic kidney disease (CKD) or in end-stage renal disease (ESRD) through quantitative alterations. …”
Get full text

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers by Ping Jin, Juan Ma, Peng Wu, Yitong Bian, Xueping Ma, Shaobin Jia, Qiangsun Zheng

Subjects: Get full text

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice by Xiaocui Chen, Minghui Sun, Xiang Ma, Yitong Ma, Bangdang Chen

“…Here, we developed a novel chimeric AAV8.P-PCSK9 short hairpin RNA (shRNA) vector that incorporates a cross-species specific shRNA targeting PCSK9 to assess its effects on lipid levels and atherosclerosis in mice. …”
Get full text

Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes by Małgorzata Waluś-Miarka, Maria Kapusta, Przemysław Miarka, Ewa Kawalec, Barbara Idzior-Waluś

“…Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL metabolism. …”
Get full text

The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes by Zeki Dogan, Abdulhalim Senyigit, Sinem Durmus, Canan Duvarcı, Remise Gelişgen, Hafize Uzun, Omur Tabak

Subjects: Get full text

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis by Yue Zhang, Yanrong Suo, Lin Yang, Xiaolu Zhang, Qun Yu, Miao Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang

“…We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. …”
Get full text

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis by Yuhua Jiang, Yingying Wang, Sijia Ma, Linlin Qian, Yeteng Jing, Xi Chen, Jinsheng Yang

Subjects: Get full text

New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia by Sushmitha Duddu, Yash T. Katakia, Rituparna Chakrabarti, Pooja Sharma, Praphulla Chandra Shukla

“…Together, these findings suggest that statin induces the colocalization of H3K4me3 and H3K9ac to transcribe PCSK9 actively and that inhibiting these marks reduces PCSK9 expression and ultimately increases hepatocyte LDL uptake. …”
Get full text

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs by S. I. Oshevski, Y. I. Ragino, E. V. Kashtanova, Y. V. Polonskaya, E. M. Stakhneva, V. P. Nikolin, N. A. Popova, N. A. Kolchanov, M. I. Voevoda

“…The following combinations of ASOs were four times injected to the mouse caudal vein: 1) ASO to apoB, 2) ASO to apoCIII, 3) ASO to apoB and ASO to PCSK9, 4) ASO to apoB, ASO to PCSK9, and ASO to apoCIII, 5) ASO to apoB (three doses), ASO to PCSK9, and ASO to apoCIII (two doses), 6) ASO to PCSK9 and (ASO to apoCIII – only in the fourth administration). …”
Get full text